Original Article
Effects of Once‐Daily and Twice‐Daily Dosing on Adherence With Prescribed Glipizide Oral Therapy for Type 2 Diabetes
Abstract
Background. We evaluated differences in adherence and persistence with prescribed therapy of once‐daily (OD) dosing compared with twice‐daily (BID) dosing of glipizide in patients with type 2 diabetes.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
